Clene opened lower at $3.87, compared with its previous close of $3.90. In the last trading session, the stock traded between $3.75 and $3.94. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Clene is now worth
$ 3.62
resulting in a loss of
$ 96.38 (96.38%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.03 (+0.77%)
Day High
$3.94
Day Low
$3.75
Day Open
$3.87
Prev Close
$3.90
Volume
23,952
1W Return
1.66%
1M Return
-4.61%
3M Return
-17.19%
6M Return
-32.24%
1Y Return
-56.98%
Fundamentals
Market Cap ($ Mn)
56
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-175.64%
EPS (TTM)
$-1.05
Investment Returns
1 Week
1.66%
1 Month
-4.61%
3 Months
-17.19%
6 Months
-32.24%
9 Months
-5.76%
Financials
Quarterly
All values in $ Mn
0.1
Mar 25
0.0
Jun 25
0.0
Sep 25
0.1
Dec 25
0.0
Mar 26
0.1
Jun 26
Updates
21Sep
Clene closes $4 million offering to fund operations through mid-2027
Clene Inc. raised $4 million via a registered direct offering of common stock. Proceeds will fund operations through mid-first quarter 2027. Offering was led by Chairman David Matlin and founding investor Kensington Capital Holdings. Potential additional $6.7 million to $7.8 million available if FDA accepts CNM-Au8 NDA for review.
1mo ago
17Aug
Clene Inc to present corporate update at Emerging Growth Conference
Clene Inc (NASDAQ: CLNN) will host a virtual corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 pm ET. The biopharmaceutical firm, focused on neurodegenerative disease treatments like CNM-Au8, will use the platform to engage with institutional and individual investors regarding its strategic direction and clinical-stage developments.
2mo ago
29Jul
Clene Inc. to present at Canaccord 46th Annual Growth Conference
Clene Inc. will present at the Canaccord 46th Annual Growth Conference in Boston on August 11, 2026. Management will discuss its pipeline for neurodegenerative diseases, including ALS and MS. The session will be webcast for remote investors.
